Guidelines for the labelling of leucocytes with 111In-oxine by Roca, Manel et al.
GUIDELINES
Guidelines for the labelling of leucocytes with
111In-oxine
Manel Roca & Erik F. J. de Vries & Francois Jamar &
Ora Israel & Alberto Signore
Published online: 3 March 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract We describe here a protocol for labelling autolo-
gous white blood cells with
111In-oxine based on previously
published consensus papers and guidelines. This protocol
includes quality control and safety procedures and is in
accordance with current European Union regulations and
International Atomic Energy Agency recommendations.
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Purpose
White blood cells (WBC) labelled with
111In-oxine (
111In-8-
hydroxyquinoline) have been successfully applied in the field
of infection/inflammation scintigraphy for many years, but
this radiopharmaceutical has been largely replaced by WBC
labelled with
99mTc-HMPAO. Still,
111In-oxine-labelled
WBC are routinely used by several centres. In fact,
111In-
oxine-labelled WBC have proved to be superior to WBC
labelled with
99mTc-HMPAO for imaging a number of spe-
cific clinical indications. Although the general procedures for
labelling of WBC with either
111In-oxine or
99mTc-HMPAO
are similar, there are some important differences between the
procedures. Despite substantial overlap with the guidelines
for the labelling of WBC with
99mTc-HMPAO, it was de-
cided to prepare separate guidelines for the labelling of WBC
with
111In-oxine, to avoid confusion and misinterpretation.
The aim of this document is to provide information on
the preparation and quality control of
111In-oxine WBC that
may assist nuclear medicine practitioners, radiopharmacists,
technicians and other individuals involved. The corre-
sponding guidelines of the Society of Nuclear Medicine, rec-
ommendations of the International Atomic Energy Agency
(IAEA), several national guidelines, and the most relevant
literature were taken into consideration and partially integrat-
ed into this text [1–25]. The present guidelines, therefore,
neither arise from a consensus conference nor from
evidence-based meta-analysis, but were produced by a panel
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their own experience, and from knowledge of colleagues
from all over the world that was shared at meetings, at
congresses and during collaborative scientific work including
multicentre studies.
This protocol aims to guide the labelling of WBC in
accordance with currently effective European Union regu-
lations. However, the specific rules in the country of interest
must also be known and applied to practice, because
different European countries have different recommendations
or laws regarding the production of extemporaneous radio-
pharmaceuticals, especially when labelled autologous cells
are considered, since they cannot be sterilized after labelling.
Therefore, the procedure may have to be adjusted to local
needs and the equipment available.
Background information
Scintigraphy with labelled autologous WBC is a widely used
method for detecting sites of infection. In the mid 1970s,
111In-oxine was introduced as a labelling agent for WBC
scintigraphy. The
111In-oxine solution is supplied in a vial as
a ready-to-use radiopharmaceutical. Indium forms an un-
charged pseudo-octahedral N3O3 complex with three mole-
cules of 8-hydroxyquinoline (oxine). The complex is a
nonspecific blood cell labelling agent, as it is neutral and
lipid-soluble, which enables it to penetrate through the
bilayer cell membrane. Within the cell, indium becomes
firmly attached to cytoplasmic components (such as lacto-
ferrin). The liberated 8-hydroxyquinoline is released by the
cell. The mechanism of labelling cells with indium
111In-
oxine is thought to involve an exchange reaction between the
8-hydroxyquinoline carrier and subcellular components which
chelate indium more strongly than 8-hydroxyquinoline. The
low stability constant of the
111In-oxine complex, estimated at
approximately 10
10, supports this theory.
In normal individuals, after injection of labelled leuco-
cytes about 60% of the radioactivity is immediately taken
up by the liver, spleen, bone marrow and other tissues.
There is only a very short transient hold-up in the lungs.
The remainder shows exponential clearance from the
circulation with a half-life between 5 and 10 h, resulting
in a final uptake of about 20% in the liver, 25% in the
spleen, 30% in the bone marrow and 25% in other organs.
Clearance of activity derived from labelled leucocytes from
liver and spleen is very slow. In addition, there is very low
excretion of activity in both the urine and feces.
For WBC scintigraphy, either mixed leucocytes or
isolated granulocytes can be used. When mixed leucocytes
are labelled with
111In-oxine, about 60–70% of the
radioactivity is bound to granulocytes. Labelled mixed
leucocytes can display higher blood pool activity, especially
in the early images, due to the presence of labelled lym-
phocytes and residual erythrocytes.
When compared to
99mTc-HMPAO-labelled WBC, there
are some advantages and disadvantages in using
111In-
oxine-labelled WBC. The main advantage of
111In-oxine
over
99mTc-HMPAO is the higher labelling efficiency (LE)
and less efflux of radioactivity from the labelled WBC. The
costs of
111In-oxine-labelled WBC are generally lower than
those of HMPAO-labelled WBC, although in some Euro-
pean countries HMPAO is available at low cost as a generic
drug. Furthermore, if a bone marrow scan is required at
24 h (usually performed with
99mTc-nanocolloids of
albumin), the use of
111In-oxine-labelled WBC does not
interfere with imaging of
99mTc-nanocolloids, because
different energy windows can be used to detect
99mTc and
111In simultaneously. Finally,
111In-labelled WBC are
preferentially indicated for imaging abdominal infections
and Inflammatory bowel disease, since there is hardly any
intestinal excretion of
111In-oxine.
On the other hand, planar images obtained with
111In-
labelled WBC are of substantially lower quality than those
obtained with
99mTc-labelled WBC. SPECT images of
111In-labelled WBC are of very low quality as well, unless
the acquisition time is largely increased. In addition,
111In-
oxine has to be ordered in advance, whereas
99mTc is
readily available from portable generators. The most
important disadvantage, however, is the radiation exposure
of labelled cells, critical organs (spleen) and the whole body
to
111In-oxine (Table 1), which is substantially higher than
that from
99mTc-HMPAO.
Common indications for
111In-oxine WBC scintigraphy
111In-oxine-labelled WBC scintigraphy may be applied to de-
tect and localize any occult site of infection and to determine
the extent of the process in various disorders, including:
& Inflammatory bowel disease
& Intra-abdominal infection
& Osteomyelitis of the appendicular skeleton
& Diabetic foot
& Infected joint and vascular prosthesis
& Lung infections
& Neurological infections
& Fever of unknown origin
& Postoperative abscesses
& Endocarditis
& Infected central venous catheters or other devices
111In-oxine-labelled WBC are particularly useful for the
detection of inflammatory sites in the abdomen, where
99mTc-HMPAO-labelled WBC are less suitable due to high
bowel excretion.
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During the labelling procedure, blood and blood compo-
nents of the patient, who could potentially be infected with
pathogens, need to be handled. To prevent contamination of
the operator who is performing the labelling, waterproof
gloves should be worn throughout the procedure. Special
caution should be taken when handling needles.
Since
111In-oxine WBC have to be reinjected into the
patient, strict aseptic conditions are required for the
labelling procedure. For this purpose, only sterile reagents
and disposable plastic-ware should be used and sterile
gloves, cap and mask should be worn. Usually, WBC are
labelled in a laminar flow cabinet or isolator installed
according to local regulations. Recently, certified sterile
closed-kit labelling devices have become available that may
represent a good approach to WBC labelling with further
protection for patient and operator, despite the fact that they
have to be used in a sterile cabinet as well.
Simultaneous labelling of WBC from multiple patients is
discouraged in order to prevent possible cross-contamination.
Labelling of WBC of different patients should be carried out
at physically separated locations, unless closed devices are
used. At all times correct identification of the patient’sb l o o d
products should be guaranteed. All syringes, tubes and any
material in contact with the patient’s blood components
should be clearly labelled with the patient’sn a m e ,b a r - c o d e
and/or colour code.
During the labelling of WBC with
111In-oxine care
should be taken not to damage the leucocytes, as this would
result in leakage of the radioactivity from the cells,
adhesion of labelled leucocytes to the vascular endothelium
(especially in the microvasculature of the lungs) and loss of
motility. To avoid degradation of the radiopharmaceutical
and radiation damage to labelled cells,
111In-oxine-labelled
WBCs should be reinjected as soon as possible, but not
later than 1 h after labelling.
Labelling of mixed leucocytes causes radiation damage
to the lymphocytes as a result of self-irradiation by internal
conversion of electrons and Auger electrons. However,
since the lymphocytes are unable to divide after labelling
and are eliminated through apoptosis and phagocytosis,
the risk of lymphoid malignancies after administration of
111In-oxine-labelled mixed leucocytes is considered to be
negligible.
Procedure
A. Isolation of WBCs
A1. Collection of blood Fill a 60-ml syringe with 9 ml of
acid-citrate-dextrose anticoagulant solution (ACD; formu-
lation A according to the European Pharmacopoeia, con-
sisting of 0.73 g of anhydrous citric acid, 2.2 g of sodium
citrate dihydrate and 2.45 g of dextrose monohydrate in
100 ml of water for injection) and add 51 ml of the patient’s
blood to this syringe. Use a needle with an inner diameter
of at least 20 G to prevent damage to the WBC. Damage is
related to shear stress due to high laminar flow in small
needles when using large syringes. Blood withdrawal
should be slow and smooth in order to prevent the
formation of bubbles and foaming. Mix the blood–ACD
solution by gently turning the syringe end over end a few
times (do not mix by shaking). At least, 2×10
8 leucocytes
are required to achieve good LE. In patients with
neutropenia (<2×10
3 neutrophils/mm
3), an additional sy-
ringe of ACD anticoagulant and blood may be needed.
Although the use of smaller volumes of blood (down to as
little as 20 ml) has been described in the literature, this is
not recommended, because it tends to reduce the LE.
Smaller blood volumes can be drawn from children,
depending on feasibility and considering that the activity is
determined according to body weight and local regulations.
In this case, the use of smaller syringes and needles is
advised (use multiple 10-ml syringes containing 1.8 ml of
ACD).
A2. Isolation of cell-free plasma Dispense 15 ml of the
blood–ACD solution into a Falcon centrifugation tube
and centrifuge at 2,000g at room temperature for 10 min.
Separate the cell-free plasma (CFP) from the pellet. The
CFP will be used as the medium for cell resuspension after
labelling. Isotonic phosphate-buffered saline, pH 7.4
(PBS), or a 0.9% aqueous solution of sodium chloride
(saline) could be used as an alternative to CFP, although
CFP is a more physiological medium. There is no
scientific evidence that supports preference of one medi-
um over another. CFP should not be used in the labelling
step, because indium-chelating plasma proteins such as
transferrin cause degradation of the
111In-oxine complex,
resulting in a low LE [24].
Table 1 Radiation dosimetry for
111In-labelled leucocytes
Population Administered
activity (MBq)
Organ receiving
the largest
radiation dose
(Spleen)
(mGy/MBq)
Effective
dose
equivalent
(mSv/MBq)
Adults 10–18.5 5.5 0.59
Children
(5 years old)
0.15–0.25/kg 17.0 1.8
International Commission on Radiological Protection. Annals of the
ICRP, Publication 53, Radiation Dose to Patients from Radiopharma-
ceuticals. Pergamon, Elsevier Science, London; 1988, pp. 255–256
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allowed to sediment with the aid of 2-hydroxyethyl starch
(10% HES, pharmaceutical grade). While several formula-
tions of HES plasma expander are commercially available,
it is highly recommended to use high molecular weight
HES 200/0.5 or 200/0.6 (mean molecular weight of 200
kDa), since formulations of lower molecular weight HES
do not work as well as a sedimentation agents for getting
leucocyte-rich plasma (LRP) from blood. Add 4.5 ml of
10% HES to the remaining 45 ml of the blood–ACD
mixture. Although a ratio of blood–ACD mixture to HES of
10:1 is recommended, the concentration of HES can be
increased up to a ratio of 5:1 for patients with polycythae-
mia or sickle-cell anaemia. Gently turn the syringe end over
end a few times. Place the syringe with the opening up and
allow the erythrocytes to sediment. This takes 30 to 45 min.
Collect the LRP in a Falcon centrifuge tube. This can be
achieved via a long lumbar needle or a butterfly needle of at
least 20 G by gently pushing the piston of the syringe up
without disturbing the erythrocytes. An alternative way
to transfer the LRP is to use a 5-inch Kwill filling tube.
Centrifuge the LRP at 150g for 5 min. Application of
higher centrifugal forces should be avoided, since this
would lead to increased platelet contamination. Lower
centrifugal forces can be applied if the centrifugation time
is adjusted accordingly. (NB: To avoid resuspension of the
leucocytes, the centrifuge’s brakes should be switched off
in all centrifugation steps.)
Remove the platelet-rich plasma (PRP) and gently
resuspend the mixed leucocyte pellet. As an optional step,
the pellet could be washed with saline (or alternatively
PBS) to reduce the number of contaminating platelets. For
this purpose, gently resuspend the pellet in 3 ml of saline
(or alternatively PBS), centrifuge at 150g for 5 min and
remove the supernatant from the leucocyte pellet. Gently
resuspend the mixed leucocytes in 1 ml of saline (or
alternatively PBS) and use this cell suspension for labelling
(step B).
A4. Isolation of granulocytes (optional) Although labelling
of mixed leucocytes (from step A3) is recommended,
purified granulocytes can be used instead. Optionally,
granulocytes can be isolated from mixed leucocytes by
gradient centrifugation. For this purpose, prepare gradient
solution A and gradient solution B. Gradient solution A
consists of A1.0 ml 9% NaCl, 5.5 ml Percoll (colloidal
silica particles coated with polyvinylpyrrolidone; GE
Healthcare, Little Chalfont, UK, or Sigma-Aldrich, St
Louis, MO) and 3.4 ml water for injection, and gradient
solution B consists of 1.0 ml 9% NaCl, 7.0 ml Percoll and
1.9 ml water for injection. Carefully inject with a syringe
4 ml of gradient solution A and subsequently 4 ml of
gradient solution B under the mixed leucocyte suspension
(i.e. at the bottom of the tube). Take care that the cell
suspension and the gradient solutions do not mix. Centri-
fuge the gradient at 150g for 30 min. The granulocytes are
now visible as a white layer between the gradient solutions,
whereas the mononuclear cells and residual platelets are on
the top of the gradient and erythrocytes are in the pellet.
Carefully aspirate the granulocyte layer with a plastic
Pasteur-type pipette and dispense them into a Falcon tube.
Add 10 ml of saline solution (or PBS) and centrifuge at 150
g for 10 min. Remove the supernatant and gently resuspend
the granulocyte pellet in 1 ml of saline (or PBS). As an easy
alternative for Percoll, Lymphoprep has been used [26], but
it has not been licensed for patient use and therefore ethical
approval is required.
B. Labelling of WBC with
111In-oxine
Aspirate approximately 20 MBq of
111In-oxine into a 1- ml
syringe from a ready-to-use radiopharmaceutical vial and
add this solution to the mixed leucocyte cell suspension (or
purified granulocytes) and incubate for 10 min at room
temperature. Usually, the
111In-oxine solution is formulated
in a buffer solution by the manufacturer. However, if an
111In-oxine solution is used without buffer, HEPES buffer
(about 6 mg/ml final concentration) can be added to ensure
a suitable pH for cell labelling. During incubation, gently
swirl the cell suspension periodically to prevent sedimen-
tation of the cells. After the incubation is complete, add at
least 3 ml (preferably up to 10 ml) of PBS or saline and
centrifuge at 150g for 5 min. After centrifugation, remove
the supernatant containing unbound
111In-oxine and mea-
sure the amount of radioactivity in the pellet and in the
supernatant to calculate the LE. Gently resuspend the pellet
containing the labelled mixed leucocytes in 3–5 ml of CFP.
Dispense the patient dose (10–18.5 MBq) from the cell
suspension. The
111In-oxine-labelled WBC should be
visually inspected and reinjected into the patient as soon
as possible, but not later than 1 h after completion of the
labelling procedure. The labelled WBC should be injected
slowly, preferably using a needle of at least 22 G (0.7 mm
diameter) to prevent cell damage due to shear stress (the
inner diameter of the needle is only approximately 50-fold
larger than the diameter of the WBC). Check the patient’s
identity prior to administration of the labelled WBC.
C. Quality controls
Several methods for quality control have been described,
although only a few of them are used regularly in clinical
routine, as many of these tests are time-consuming. For
routine clinical use, visual inspection of final product and
determination of the LE are usually considered sufficient.
Because
111In-oxine is more toxic to the cells than
99mTc-
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inspection and trypan blue exclusion test) are highly
recommended. A retrospective sterility test could be used
as additional quality controls, when desired. All these tests
should be included when setting up the methodology for its
validation, or when a new variation in the method is
introduced. Early in-vivo lung uptake and liver-to-spleen
activity ratio are the most commonly used in-vivo indices
of problems with radiolabelling.
For process validation, operator validation or periodic
process control, additional functional tests such as chemo-
taxis or phagocytosis assays may be included, but this is not
required for routine use.
C1. Visual inspection (recommended routinely) Visual
inspection of the preparation searching for clumps, clots,
fibrin and platelet aggregates should be performed through-
out the procedure and in particular after resuspending the
pellet of cells after centrifugation. At the end of the pro-
cedure, and before collecting the labelled cells in the
syringe for administration to patients, the inspection should
be performed carefully by gently rotating the vial. In case
of aggregates, they should be dissolved by gently shaking
or pipetting the sample. If clumps cannot be dissolved, the
preparation should not be injected.
C2. Labelling efficiency (recommended routinely) After
each production, the LE should be determined by measur-
ing the amount of radioactivity in the supernatant (soluble
111In compounds) and the pellet (cell-associated
111In) of
the labelling solution after centrifugation. The LE can be
calculated using the formula:
LE ¼
radioactivity in pellet
radioactivity in pellet þ radioactivity in supernatant
  100
A LE between 50% and 80% is expected. If the LE is
<50% further quality controls should be performed, such as
microscopic inspection and trypan blue exclusion test for
cell viability (see step C4).
C3. Sterility (recommended periodically) For post-release
sterility testing, tests should be performed in accordance with
the method described in the most recent European Pharma-
copoeia. This test is preferably performed by a microbiolo-
gist, and may vary from centre to centre according to local
needs and experience. The sterility test has to be performed
in triplicate for the validation of the procedure and in case of
any modification to the procedure, including new personnel
and new reagents. The recent availability of media fills
allows validation and revalidation of the labelling procedure
with sterility control of each single step of the labelling
procedure. If sterility tests are not passed, the process needs
to be revalidated. A test for contamination of solutions and
reagents with pyrogens (Limulus test, LAL test; PBI
International, Milan, Italy, or Endosafe-PTS, Charles River
Laboratories, L’Arbresle, France) can also be used in
addition to sterility tests. The method is described in detail
in the current European Pharmacopoeia.
C4. Trypan blue exclusion test, clumping and cell counting
(recommended periodically) Add 25µl of 0.4% trypan blue
solution in water to 25µl of the labelled leucocyte cell
suspension (from step B) and gently mix the solution. Put
a drop of the blue mixture in a haemocytometer and place
the haemocytometer under a phase-contrast microscope at
100-fold magnification. Check the counting chamber for
clumps and microaggregates of cells, count the number of
cells and count the percentage of blue-stained cells (cells
that have been damaged during de labelling process). As a
control, repeat the same procedure using unlabelled
leucocytes (from step A3). A preparation with a percentage
of dead cells (blue-stained cells) of >4% should not be
released for injection into the patient, and consequently new
tests for validation of the method should be undertaken.
C5. Cell subset recovery test (recommended for initial
validation) The test consists of counting the number of
different cell subsets present during the separation and
labelling procedure to verify that red blood cell and platelet
contamination are within an acceptable ranges. After each
crucial step (usually after centrifugations and at the end of
procedure) collect a drop of resuspended cells and dispense
it into a 5-ml vial with 1 ml saline or PBS. Count the cells
using a routine cytofluorimeter for haematology or a hemo-
cytometer slide viewed under an optical microscope. Limits
of acceptability in the final cell suspension are: erythrocyte/
WBC ratio<3 and platelet/WBC ratio<1.
C6. Measurement of cell efflux of
111In (recommended for
initial validation) Despite irreversible binding of
111In to
nuclear and cytoplasmic proteins, damaged leucocytes may
release more radioactivity and at a higher rate than intact
cells. Efflux can be measured by preparing three aliquots of
labelled leucocytes and incubating them at 37°C. After 1 h,
the aliquots are centrifuged at 150 g for 10 min and the
amounts of radioactivity in the pellet and supernatant are
counted separately. A release of <5% (i.e. radiochemical
purity >95%) at 1 h is acceptable.
C7. In vivo lung uptake (recommended routinely) Early,
temporary lung uptake of labelled leucocytes can be
normal. However, lung images acquired at 30 min after
injection should show an almost complete clearance of lung
activity. Focal spots of radioactivity in the lungs at 30 min
or later indicate the presence of radiolabelled clumps of
cells in the injection sample. Diffuse lung activity, intense
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of cell damage as a result of the labelling procedure, in
particular in patients without any known lung disease.
In general, four different patterns of lung activity can be
observed:
1. Rapid transit of cells in the lung with disappearance of
radioactivity within 5 min.
2. Delayed lung transit of labelled cells, but with complete
clearance within 30 min.
3. Prolonged focal or diffuse retention of lung activity with
disappearance within 3 h of injection.
4. Delayed lung transit (as in 2) with increased liver activity
greater than spleen activity.
Patterns 1 and 2 are normal. Patterns 3 and 4 indicate
cell damage, the examination is nondiagnostic and partic-
ular care should be taken with image interpretation. (NB:I t
must be kept in mind that some disease processes can be
associated with diffuse lung activity and/or delayed wash-
out of labelled WBC.)
Lung transit is a qualitative test. In case of doubt, a
quantitative test of liver-to-spleen ratio can be performed as
described below.
C8. In vivo liver-to-spleen ratio (recommended periodically)
Normally, at any time point, spleen activity should be higher
than liver activity. Tissue activity can be quantified by region
of interest analysis and should be normalized to the area of
the region of interest. A liver activity the same as or higher
than spleen activity indicates cell damage, the scan may be
nondiagnostic and particular care should be taken with image
interpretation.
Methodological issues requiring further clarification
& The optimal formulation of HES plasma expander and
the value of alternatives, such as succinylated gelatin
and methyl cellulose.
& The use of PRP instead of CFP, or PBS or saline for
centrifugation after the labelling.
& The use of PBS as an alternative for CFP for recon-
stitution of labelled WBC.
& The use of gradient solution for granulocyte separation.
& Qualification and training of personnel required for WBC
labelling.
& Requirements for equipment and infrastructure where
WBC labelling is performed.
Closed disposable sterile systems for WBC labelling
The recent availability of a closed disposable sterile system
(Leukokit; GE Healthcare, Little Chalfont, UK) for WBC
separation and labelling offers an additional advantage for
operator protection and for avoiding sample contamination.
It is a licensed medical device distributed worldwide that
may allow simplification of the required infrastructure,
although to date there is no defined legislation for the use of
this type of product in a different way from that of open
systems. The kit includes a sterile GMP-produced vial of
anticoagulant agent (ACD-A), a vial of 10% HES and a vial
of PBS for cell washing and resuspension, thus avoiding
possible causes of contamination of the labelled product.
Procedure and personnel validation
The WBC labelling process must be simulated for validation
of the process prior to starting clinical studies in a specific
laboratory. It is recommended that the requirements for the
validation procedure are more strict than those for regular
quality control. The validation procedure should include
control of LE (>60%), sterility test (negative), pyrogenicity
(absent), viability of cells (>98%), cell subset recovery test
(in final cell suspension erythrocyte/WBC ratio <3) and
measurement of “in vitro” cell efflux of
111In within the first
hour after labelling (<5%, i.e. radiochemical purity >95%).
Sterility tests can be done with media fills or using different
culture media. Tests may vary considerably and may include
bacterial growth medium (e.g. agar) plates for environmental
monitoring and hand-wash plates for hand wash validation.
Procedure and personnel validation should be performed
at least three times for each new operator prior to initiation
of clinical studies and should be repeated at regular inter-
vals (suggested every 6 months) and after a significant
change in the method or reagents.
At the moment, no country has defined by law a quali-
fication, course or course programme for training of per-
sonnel. Except for defined local regulations, it is accepted that
specifically trained medical doctors, radiopharmacists, phar-
macists, chemists, radiochemists, biologists, or technicians
perform the labelling of WBC under the supervision and
responsibility of the Qualified Person, who is ultimately
responsible for quality control and quality assurance. In
this context, a training programme accepted worldwide for
personnel who will be performing radiolabelling of blood
elementsisadvisableandalsosuggestedbyotherinternational
organizations such as IAEA and ISORBE.
Briefly, a training course for personnel should include at
least:
& General information on radioprotection and use of
isotopes
& (Local) rules and recommendations
& Study of available guidelines and pharmacopoeia
& Guidelines for working in aseptic conditions, including
the use of a Class IIa safety cabinet
840 Eur J Nucl Med Mol Imaging (2010) 37:835–841& Information on equipment operation and its maintenance
& Practical skills in labelling cells and blood elements
& Practical skills in performing required in vitro quality
controls
& Recommendations for record-keeping
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